Oxaliplatin and capecitabine (CAPOX) is active and feasible for irinotecan refractory metastatic colorectal carcinoma (MCRC)

被引：0

作者：

Munoz, Alberto ^{[1
]}

Viteri, Ainboa ^{[1
]}

Rubio, Itziar ^{[1
]}

Alvarez, Aitor ^{[1
]}

Mane, Joan M. ^{[1
]}

Pardo, Marta ^{[1
]}

Fernandez, Ricardo ^{[1
]}

Lopez-Argumedo, Gonzalo ^{[1
]}

Barcelo, Ramon ^{[1
]}

Lopez-Vivanco, Guillermo ^{[1
]}

机构：

[1] Hosp Cruces, Baracaldo, Spain

来源：

ANNALS OF ONCOLOGY | 2004年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：92 / 92

页数：1

共 50 条

[1] Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy.
Grothe, W
Arnold, D
Peinert, S
Voigt, W
Loeffler, LM
Siewczynski, R
Steps, G
Boehme, J
Graeven, U
Schmoll, HJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 288S - 288S
[2] Combination of oxaliplatin and capecitabine (CAPOX) in first and second-line treatment for metastatic colorectal carcinoma (MCRC).
Lopez-Vivanco, G
Muñoz, A
Mañe, JM
Ferreiro, J
Rubio, I
Fuente, N
Perez-Hoyos, T
Lopez-Argumedo, G
Viteri, A
Barcelo-Galindez, R
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 294S - 294S
[3] Oxaliplatin and Capecitabine (CAPOX) in Non Selected Patients With Metastatic Colorectal Cancer (MCRC) After First-line Irinotecan Based Regimen
Fonseca, P. J.
Solis, P.
Vieitez, J. M.
Izquierdo, M.
Pardo, P.
Gutierrez, E.
Perez, Q.
Alvarez, C.
Frunza, M.
Uriol, E.
[J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S423
[4] A prospective study of oxaliplatin and capecitabine (CapOx) in metastatic colorectal cancer (MCRC) with baseline stratification according to resectability status
Watkins, D. J.
Jackson, C.
Chua, Y.
Chong, G.
Norman, A. R.
Brown, G.
Mudan, S.
Karanjia, N.
Cunningham, D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[5] Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
Cupini, S.
Bursi, S.
Masi, G.
Loupakis, F.
Barbara, C.
Barletta, M. T.
Baldi, G. G.
Vasile, E.
Fornaro, L.
Petrini, I.
Allegrini, G.
Antonuzzo, A.
Di Marsico, R.
Andreuccetti, M.
Ricci, S.
Falcone, A.
[J]. ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
[6] A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.
Overman, Michael J.
Eng, Cathy
Kee, Bryan K.
Fogelman, David R.
Fark, Christine
Hippert, Rick
Holter, Scott
Issa, Jean-Pierre
Hamilton, Stanley R.
Kopetz, Scott
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[7] Final results of a randomized comparison of infusional 5-fluorouracil/leucovorin plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) in metastatic colorectal carcinoma (MCRC)
Porschen, Rainer
Kubicka, S.
Grothey, A.
Grateven, U.
Kretzschmar, A.
Greil, R.
Freier, W.
Seufferlein, T.
Arkenau, Ht
Hinke, A.
Schmoll, Hj
Schmiegel, W.
[J]. GASTROENTEROLOGY, 2006, 130 (04) : A582 - A582
[8] CAPECITABINE AND OXALIPLATIN (CAPOX) PLUS CETUXIMAB IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA WHO PROGRESSED AFTER OXALIPLATIN-BASED CHEMOTHERAPY
Petrovic, Z.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 135 - 135
[9] Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
Cupini, S.
Bursi, S.
Masi, G.
Loupakis, F.
Barbara, C.
Fornaro, L.
Allegrini, G.
Di Marsico, R.
Andreuccetti, M.
Falcone, A.
[J]. EJC SUPPLEMENTS, 2007, 5 (04): : 251 - 251
[10] SUNCAP, a phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin.
Samson, B.
Latreille, J.
Nguyen, N. T.
Sperlich, C.
Berbiche, D.
Tournigand, C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)

← 1 2 3 4 5 →